Completed PHASE1 INTERVENTIONAL 2-arm NCT00675064

Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Doses Of GSK369796 In Healthy Subjects

Single-blind, Placebo-controlled, Randomized Study Testing Single Ascending Doses of GSK369796 in Healthy Subjects

Sponsor: GlaxoSmithKline

Conditions Malaria

Updated 7 times since 2017 Last updated: Sep 11, 2018 Started: May 2, 2008 Primary completion: Oct 12, 2008 Completion: Oct 12, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Malaria, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2008. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Oct 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Oct 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Aug 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Aug 2017 [monthly]

Completed PHASE1

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Medicines for Malaria Venture

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom